Waldencast H1 2026 net loss from continuing operations widens 97% to $94.9 million; revenue drops 57% to $26.1 million

PUBT · 1d ago
Waldencast H1 2026 net loss from continuing operations widens 97% to $94.9 million; revenue drops 57% to $26.1 million
  • Waldencast reported H1 2026 net revenue from continuing operations of USD 26.1 million, down 57% year over year.
  • Net loss from continuing operations widened to USD 94.9 million.
  • Gross margin fell to 53.7% from 67.3% a year earlier.
  • Results include a non-cash goodwill impairment charge of USD 52.3 million against the Milk Makeup reporting unit.
  • Obagi Medical was sold to Bridgepoint on July 30; Class A shares and warrants are set to delist from Nasdaq.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840199-26-000108), on September 28, 2026, and is solely responsible for the information contained therein.